Scotiabank initiated coverage on Mirati Therapeutics
$MRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Scotiabank initiated coverage of Mirati Therapeutics with a rating of Sector Underperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/10/2023 | $51.00 → $48.00 | Neutral → Buy | Citigroup |
| 8/9/2023 | $45.00 | Neutral → Buy | B. Riley Securities |
| 8/9/2023 | $45.00 | Overweight | Piper Sandler |
| 7/27/2023 | Sector Underperform | Scotiabank | |
| 5/25/2023 | Perform → Outperform | Oppenheimer | |
| 12/14/2022 | Hold | Needham | |
| 12/9/2022 | $121.00 → $53.00 | Buy → Neutral | Citigroup |
| 12/8/2022 | $110.00 → $59.00 | Outperform → Market Perform | BMO Capital Markets |
Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity
Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity
Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Efficacy
Citigroup upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $48.00 from $51.00 previously
B. Riley Securities upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $45.00
Piper Sandler resumed coverage of Mirati Therapeutics with a rating of Overweight and set a new price target of $45.00